EBIT -9% vs cons, -15% vs ABGSC Order backlog +25%, organic growth +43% y-o-y We expect limited esti...
50% y-o-y organic sales growth in Q2'25e EBIT forecasts raised by 1.
Q2'25e organic sales growth of 45% y-o-y We raise '25e paying users by 2% FVR of SEK 30-45 reiterate...
Alisa Bank’s H1 was slightly weaker than expected. We remain cautious on near-term development but n...
Redeye updates in Better Collective ahead of Q2-results (due 20 August after market close) where we ...
Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway.
Raute’s margins impress, while extended low orders pose big earnings headwinds, yet multiples remain...
The economic environment and end demand has not been very favourable for Aspo.
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a das...
EQL Pharma redovisade ökad nettoomsättning och EBIT i det första kvartalet.
The company’s adjusted EBITDA was EUR 3.1m (pre-announced) in Q2.
Redeye gives its preview on OssDsign’s Q2 2025 report, due on August 19.
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech.
Raute’s EUR 43.8m Q2 top line came in clearly below our estimate, yet the EUR 6.
Endomines reports its H1 figures on 14th of August.
Market conditions remain unfavourable for Aurdel Septon divestment carries largest impact on estimat...
Q2 report due on Thursday, 14 August Sales and margin downgrades in Germany weigh on estimates Tradi...
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track D...
Q2e sales of SEK 52m, 22% y-o-y, adj. EBIT of SEK 17m (12m) FX headwinds, but we expect customer gro...
